Physician profile
Andrew S Wang
NPI 1134387335
$3,283.35
in general payments reported to CMS, 2019-2025
29 companies · $77.32 in 2025
The $77.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $793 · 2021: $435 · 2023: $191 · 2024: $93.66 · 2025: $77.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $425.46 | 2019-2021 | |
| Novo Nordisk INC | $394.33 | 2019-2021 | |
| Amgen INC. | $279.34 | 2019-2025 | Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $263.65 | 2019-2020 | |
| Amarin Pharma, INC. | $192.91 | 2019-2021 | |
| Abbvie INC. | $184.99 | 2019-2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.43 | 2019-2021 | |
| Pfizer INC. | $168.74 | 2019-2021 | |
| Alkermes, INC. | $143.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.70 | 2019-2021 | |
| Allergan, INC. | $119.39 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.03 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $112.57 | 2019-2021 | |
| Glaxosmithkline, LLC. | $60.52 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $58.14 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $49.42 | 2023 | Loreev Xr, Gralise |
| Phadia US INC. | $46.45 | 2023-2024 | Immunocap |
| Astellas Pharma US INC | $45.74 | 2019-2021 | |
| Dexcom, INC. | $40.57 | 2024-2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $38.61 | 2019 | |
| Eisai INC. | $36.54 | 2020-2021 | |
| Boston Scientific Corporation | $34.67 | 2025 | Moses |
| Merck Sharp & Dohme LLC | $31.46 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Dynavax Technologies Corporation | $23.38 | 2024 | Heplisav-B |
| Regeneron Healthcare Solutions, INC. | $23.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.19 | 2020 | |
| Celgene Corporation | $22.14 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.89 | 2021 | |
| Vivus LLC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.